Thanks for posting @Merino1 I wish some of these tasks were...

Thanks for posting @Merino1

I wish some of these tasks were outsourced, such as patient recruitment, to professional bodies who specialise in the field on a daily basis. Perhaps then the issues surrounding recruitment in the Her Vaxx Keytruda combination trial may have been avoided. If they were indeed outsourced, (which to the best of my knowledge they weren't), clearly a more efficient provider needs to be enlisted. I know I've spoken before about it but by outsourcing such activities as corporate advisory (capital raises, strategic planning M&A activities), marketing, communications and PR, or clinical trial recruitment, external bodies can be held accountable for their performance, or lack thereof. The IMU Board can be kept duly informed, as can shareholders, in a timely manner. Figures surrounding patient dosed numbers can be made readily available to shareholders (i.e, the owners of the company). Conflicts of interest and whispers surrounding them (e.g., CHM, ALA) can be avoided through the contracting of third party experts. Whilst most importantly Imugene can maintain their focus on what it is they do best, creating meaningful data that is ultimately approved by the FDA for manufacturing and administration to patients.

I like you, to use your words, have been hoping/thinking they'll offload something in the B Cell platform any day now, surely MS wants to earn his KPI's. But we wouldn't know would we, as like everything IMU its all in house, with no external accountability.

@Hawkbar33 thanks for posting. This all looks very interesting doesn't it. Perhaps Imugene should have looked at acquiring this vehicle to compliment their existing push into the solid tumour arena some time ago, before it developed a head of steam. Maybe if Paul Hopper wasn't directly linked to both organisations that may have been able to occur at a reasonable price tag. No doubt it could prove all a bit expensive for Imugene now.

I'll have to perform some more research on ALA's value proposition. Maybe @Steini can assist. I think he may be across it.

DYOR